Loading, please wait...
.webp&w=384&q=75){kind=logo}
Verifying...
Loading, please wait...
"Wherever the art of Medicine is loved, there is also a love of Humanity."
Hippocrates
Erdheim-Chester disease (ECD) is a multisystemic histiocytic neoplasm often identified by skeletal and visceral involvement. However, recent medical literature emphasizes the importance of recognizing atypical Erdheim-Chester disease skin lesions. Specifically, some patients develop glomeruloid haemangiomas and extensive angiomas. These lesions occur even when the classic features of POEMS syndrome are absent. Investigators have linked these findings to markedly elevated levels of vascular endothelial growth factor-A (VEGF-A).
Research demonstrates that MAPK-activated histiocytes drive these skin changes through a paracrine mechanism. Molecular analyses show that the histiocytes themselves harbor the activating mutations rather than the endothelial cells. Consequently, these histiocytes secrete VEGF-A, which stimulates localized blood vessel growth. This unique pathway explains why vascular proliferations appear in these patients. Furthermore, this mechanism differentiates these lesions from those caused by intrinsic vascular mutations.
Notably, the presence of glomeruloid haemangiomas often suggests POEMS syndrome. However, in the context of ECD, these lesions emerge due to systemic cytokine elevations. Clinicians should therefore screen patients with atypical vascular lesions for underlying histiocytic disorders. Treatment often targets the underlying MAPK pathway using BRAF or MEK inhibitors. Monitoring VEGF-A levels may also provide insight into disease activity and treatment response.
The most common skin findings are periorbital xanthelasma-like lesions. However, atypical vascular lesions like glomeruloid haemangiomas can occur due to high VEGF-A levels.
Histiocytes with MAPK mutations produce VEGF-A. This factor acts on nearby blood vessels to cause abnormal proliferation, leading to angiomas in the skin.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a professional relationship. Refer to the latest local and national guidelines for clinical practice.
References
Link will be sent via SMS to your number.
Recent studies reveal that Erdheim-Chester disease can manifest as glomeruloid haemangiomas driven by elevated VEGF-A levels. This discovery highlights a paracrine mechanism involving MAPK-activated histiocytes, providing new insights into the atypical cutaneous manifestations of this rare histiocytic neoplasm.
2 days back
A new study using Mendelian Randomization and prospective observation identifies a causal link between sarcopenia traits—specifically walking pace and muscle quality—and reduced sepsis risk, offering new avenues for early risk stratification in the ICU.
Today
A recent study highlights how psychological and somatic menopause symptoms significantly impair work productivity. Learn why clinical intervention and workplace support are essential for maintaining the professional performance and well-being of menopausal women in the workforce.
Today
A new study reveals that extracellular matrix proteins like PRO-C3 and PRO-C7 are potent risk markers for kidney disease and cardiovascular events in type 1 diabetes. These collagen biomarkers offer a non-invasive way to predict complications, potentially improving long-term patient management.
Yesterday
A retrospective analysis of orthopaedic trauma patients shows a direct link between higher opioid utilization and poor inpatient sleep quality. Each additional morphine milligram equivalent (MED) reduces total sleep time by 2.7 minutes, emphasizing the need for opioid-sparing pain management.
Today
A Swedish RCT shows that using EU-TIRADS for selective thyroid cytology doubles the yield of Bethesda IV-VI nodules (26% vs 13%) while reducing biopsy frequency from 83% to 71%. The findings support EU-TIRADS as a safe method to omit unnecessary FNAs without missing thyroid malignancies.
Yesterday